ApconiX Welcomes Dr Karin Burnett to The Team.

ApconiX is delighted to welcome Dr Karin Burnett, an experienced project toxicologist with a broad knowledge of toxicology and chemical risk assessment in the pharmaceutical industry.  Karin will join the team of experts in nonclinical safety toxicology at ApconiX, who cover all major safety disciplines and are committed to advancing the science of drug safety.

Karin Burnett graduated from the University of Surrey with a BSc in Biochemistry (Toxicology).  She attained her Diploma from the Institute of Biology in Toxicology (DIBT) and then went on to study for a PhD at the University of Birmingham, investigating mechanisms of liver non-genotoxic carcinogenesis.

Karin has extensive experience in the area having worked for a number of pharmaceutical companies including Zeneca, SmithKline Beechams and Shire Pharmaceuticals.  More recently Karin has worked with Public Health England and Imperial College, London (Toxicology Unit) as a scientific writer compiling detailed literature reviews on a wide variety of subjects for the government advisory Committees on Carcinogenicity (COC) and Mutagenicity (COM).

Karin joins the team to work in project toxicology and on target safety assessments, “I am looking forward to working with such a skilled team at ApconiX and bringing my own comprehensive experience of nonclinical programme strategy development to the team.”

Professor Ruth Roberts added, “We are very excited to have Karin on board.  With such a broad experience of toxicology, she will provide input into many aspects of the business especially Target Safety Assessments and other expert scientific reports.  It is vital to understand the potential unintended consequences of target modulation and Target Safety Reports form a key part of risk assessment and risk mitigation plans in drug discovery and development.”

By |2018-11-28T16:37:14+00:00December 12th, 2018|Target Safety Assessments, Careers|Comments Off on ApconiX Welcomes Dr Karin Burnett to The Team.

About the Author:

Professor Ruth A Roberts, PhD, ATS, FBTS, ERT, FRSB, FRCPath Director and Cofounder, ApconiX, UK and Chair and Director of Drug Discovery, University of Birmingham, UK Ruth is chair of drug discovery at Birmingham University, UK and Cofounder of ApconiX, an integrated toxicology and ion channel company that brings together a team of world-renowned nonclinical safety experts with over 400 years of drug discovery and development experience. Previously, Ruth was Global Head of Regulatory Safety at AstraZeneca and Director of Toxicology for Aventis. Ruth is an established science professional bringing rigorous expert thinking to toxicology, drug discovery and drug development. With >140 publications in peer reviewed journals, she is focused on reducing attrition attributable to safety and toxicity. A former president of the British Toxicology Society, former president of EUROTOX, former secretary to SOT and president elect of the Academy of Toxicological Sciences, Ruth was the recipient of the SOT Achievement award in 2002, the EUROTOX Bo Holmstedt Award in 2009 and the SOT Founders award in 2018 for outstanding leadership in toxicology.